Tadalafil for the treatment of pulmonary arterial hypertension: A double-blind 52-week uncontrolled extension study

Journal of the American College of Cardiology

Volumn 60, Issue 8, 2012, Pages 768-774

  Oudiz, Ronald J ^a   Brundage, Bruce H ^b   Gali, Nazzareno ^c   Ghofrani, Hossein Ardeschir ^d   Simonneau, Gerald ^e   Botros, Fady T ^f   Chan, Melanie ^f   Beardsworth, Anthony ^f   Barst, Robyn J ^g  

^a UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d JUSTUS LIEBIG UNIVERSITY   (Germany)

^e Antoine Bclre University Hospital   (France)

^f ELI LILLY AND COMPANY   (United States)

^g Columbia University College of Physicians and Surgeons ^*  (United States)

Author keywords

PDE 5; pulmonary arterial hypertension; tadalafil

Indexed keywords

BOSENTAN; PLACEBO; TADALAFIL;

ADULT; ARTICLE; BACKACHE; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FEMALE; FUNCTIONAL STATUS; HEADACHE; HEART PALPITATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PERIPHERAL EDEMA; POST HOC ANALYSIS; PRIORITY JOURNAL; PULMONARY HYPERTENSION; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; TREATMENT DURATION; TREATMENT OUTCOME; UPPER RESPIRATORY TRACT INFECTION; WALKING;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTIHYPERTENSIVE AGENTS; CARBOLINES; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; HYPERTENSION, PULMONARY; MALE; MIDDLE AGED; PHOSPHODIESTERASE 5 INHIBITORS; PROSPECTIVE STUDIES; SULFONAMIDES; TREATMENT OUTCOME; VASODILATOR AGENTS;

EID: 84865128907     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2012.05.004     Document Type: Article

References (12)

1. R.M. Tuder, S.H. Abman, T. Braun Development and pathology of pulmonary hypertension J Am Coll Cardiol 54 2009 S3 S9
2. K.M. Chin, L.J. Rubin Pulmonary arterial hypertension J Am Coll Cardiol 51 2008 1527 1538 (Pubitemid 351508372)
3. N. Gali, A. Manes, L. Negro, M. Palazzini, M.L. Bacchi-Reggiani, A. Branzi A meta-analysis of randomized controlled trials in pulmonary arterial hypertension Eur Heart J 30 2009 394 403
4. N. Gali, B.H. Brundage, H.A. Ghofrani Tadalafil therapy for pulmonary arterial hypertension Circulation 119 2009 2894 2903
5. N. Gali, M.M. Hoeper, M. Humbert Guidelines for the diagnosis and treatment of pulmonary hypertension: the Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT) Eur Heart J 30 2009 2493 2537
6. L.J. Rubin, D.B. Badesch, T.R. Fleming Long-term treatment with sildenafil citrate in pulmonary arterial hypertension: the SUPER-2 study Chest 140 2011 1274 1283
7. N. Gali, L. Negro, G. Simonneau The use of combination therapy in pulmonary arterial hypertension: new developments Eur Respir Rev 18 2009 148 153
8. L. Rubin, G. Simonneau Perspective on the optimal endpoints for pulmonary arterial hypertension trials Curr Opin Pulm Med 16 Suppl 2010 S43 S46
9. S. Provencher, O. Sitbon, M. Humbert, S. Cabrol, X. Jais, G. Simonneau Long-term outcome with first-line bosentan therapy in idiopathic pulmonary arterial hypertension Eur Heart J 27 2006 589 595
10. V.V. McLaughlin, O. Sitbon, D.B. Badesch Survival with first-line bosentan in patients with primary pulmonary hypertension Eur Respir J 25 2005 244 249 (Pubitemid 40246523)
11. V.V. McLaughlin, A. Shillington, S. Rich Survival in primary pulmonary hypertension: the impact of epoprostenol therapy Circulation 106 2002 1477 1482
12. R.J. Oudiz, N. Gali, H. Olschewski Long-term ambrisentan therapy for the treatment of pulmonary arterial hypertension J Am Coll Cardiol 54 2009 1971 1981